SAN DIEGO (PRWEB) June 17, 2020
January Therapeutics, Inc., a biopharmaceutical research and development company, today announced a research collaboration with City of Hope, a world-renowned independent research and treatment center for cancer, diabetes and other life-threatening diseases.
The collaboration centers around the application of January’s proprietary Chemistry-enabled Albumin Nanoparticle (CAN) platform to an existing City of Hope drug candidate (a nucleoside- based therapy) that is currently under investigation by City of Hope at the cancer center’s main campus near Los Angeles, California.
“January Therapeutics is thrilled to work alongside City of Hope to apply our novel albumin nanoparticles to their investigational therapy,” said Sam Ellis, CEO of January Therapeutics. Scientists from January will encapsulate the drug candidate in the company’s albumin nanoformulation. Subsequent studies of this new chemical entity will then be conducted by the research teams at City of Hope.
“City of Hope is excited to evaluate the impact that January’s platform can have on our investigational therapy,” said Steven T. Rosen, M.D., provost and chief scientific officer at City of Hope, noting that the concept of albumin encapsulation has been scientifically validated as a means of targeting cancer cells.
The details of the collaboration were not released, but the company indicated that the collaboration may potentially expand as data from the research becomes available.
About January Therapeutics
January Therapeutics is a research and development biotechnology company focused on discovering novel therapeutics that leverage the proven clinical benefits of protein-based nanoparticle formulations. January’s initial three development programs are focused on oncology, specifically related to therapeutics that treat advanced ovarian, sarcoma, lung, pancreatic and other solid tumors. January also has undisclosed strategic collaborations with two separate pharmaceutical companies.